Cassava Sciences Inc vs Twilio Inc — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Twilio Inc trades at $245.5 (market cap $39.31B). The key difference: Twilio Inc is far larger — about 823.2× Cassava Sciences Inc's market cap, and Twilio Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TWLO | |
|---|---|---|
Market Cap | $47.75M | $39.31B |
Sector | Health | Technology |
52-Week High | $4.64 | $255.95 |
52-Week Low | $0.87 | $95.23 |
Enterprise Value | -$34.93M | $37.72B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Twilio (TWLO) trades at $247.10, down 1.18% on the day, but remains near its 52-week high after a strong rally driven by Q2 2026 earnings beats and raised guidance. The stock shows bullish technical signals with support at $246 and resistance at $259. Revenue growth accelerated to 22% year-over-year in Q2, with net income turning positive in 2025 after years of losses, reflecting improved profitability and cash flow generation.
Outlook is positive with Wall Street consensus Buy rating and $266.31 price target, though high valuation multiples (P/E 35.35) and overbought RSI levels suggest near-term consolidation risk. Key opportunities include AI-driven growth and expanding free cash flow margins, while risks involve competitive pressures and execution on guidance.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →